News Column

Juno Closes $134M Series B Round

August 18, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced that it has closed its Series B round with $134M in new investment (see also Juno Therapeutics).

http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO

This latest round includes new investments by ten public mutual funds and healthcare-focused funds. All major prior investors participated as well. The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.

Juno announced the close of its $176M Series A in April. Combining the A and B rounds, Juno has raised more than $300M in less than 12 months.

"Juno continues to make significant progress in developing new therapies with the potential to radically change the outlook for patients battling cancer," said Hans Bishop, CEO of Juno. "We are delighted by the vote of confidence coming from new Series B investors and founding investors alike. Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies."

Leerink Partners LLC acted as exclusive financial advisor in this transaction.

Juno Therapeutics launched in December 2013 and was co-founded with financial support from ARCH Venture Partners and the Alaska Permanent Fund through a partnership managed by Crestline Investors.

Keywords for this news article include: Juno Therapeutics, Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters